157 related articles for article (PubMed ID: 38041763)
21. Diagnostic performance of flexible sigmoidoscopy combined with fecal immunochemical test in colorectal cancer screening: meta-analysis and modeling.
Niedermaier T; Weigl K; Hoffmeister M; Brenner H
Eur J Epidemiol; 2017 Jun; 32(6):481-493. PubMed ID: 28667446
[TBL] [Abstract][Full Text] [Related]
22. Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
Law J; Rajan A; Trieu H; Azizian J; Berry R; Beaven SW; Tabibian JH
Dig Dis Sci; 2022 Jul; 67(7):2842-2848. PubMed ID: 34350518
[TBL] [Abstract][Full Text] [Related]
23. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
24. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
25. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
[TBL] [Abstract][Full Text] [Related]
26. Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients.
Guimarães DP; Fregnani JH; Reis RM; Taveira LN; Scapulatempo-Neto C; Matsushita M; Silva SRM; Oliveira CZ; Longatto-Filho A; Eklund C; Paloheimo L; Mauad E; Suovaniemi O; Syrjänen K
Anticancer Res; 2019 Jan; 39(1):261-269. PubMed ID: 30591467
[TBL] [Abstract][Full Text] [Related]
27. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
[TBL] [Abstract][Full Text] [Related]
28. Disparities in Colorectal Cancer Screening Practices in a Midwest Urban Safety-Net Healthcare System.
Elangovan A; Skeans J; Lalani I; Ullah F; Roy A; Kaelber DC; Cooper GS; Sandhu DS
Dig Dis Sci; 2021 Aug; 66(8):2585-2594. PubMed ID: 32816217
[TBL] [Abstract][Full Text] [Related]
29. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.
Meester RG; Zauber AG; Doubeni CA; Jensen CD; Quinn VP; Helfand M; Dominitz JA; Levin TR; Corley DA; Lansdorp-Vogelaar I
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1445-1451.e8. PubMed ID: 27211498
[TBL] [Abstract][Full Text] [Related]
30. Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
Thomsen MK; Pedersen L; Erichsen R; Lash TL; Sørensen HT; Mikkelsen EM
Br J Cancer; 2022 May; 126(8):1229-1235. PubMed ID: 35058592
[TBL] [Abstract][Full Text] [Related]
31. Identification and Validation of MicroRNA Profiles in Fecal Samples for Detection of Colorectal Cancer.
Duran-Sanchon S; Moreno L; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Martín A; Serradesanferm A; Pozo À; Costa R; Lacy A; Pellisé M; Lozano JJ; Gironella M; Castells A
Gastroenterology; 2020 Mar; 158(4):947-957.e4. PubMed ID: 31622624
[TBL] [Abstract][Full Text] [Related]
32. Potential for prevention: a cohort study of colonoscopies and removal of adenomas in a FIT-based colorectal cancer screening programme.
Larsen MB; Njor SH; Jensen TM; Ingeholm P; Andersen B
Scand J Gastroenterol; 2019 Aug; 54(8):1008-1014. PubMed ID: 31397598
[No Abstract] [Full Text] [Related]
33. Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer.
Zorzi M; Hassan C; Capodaglio G; Baracco M; Antonelli G; Bovo E; Rugge M
Endoscopy; 2020 Oct; 52(10):871-876. PubMed ID: 32356282
[TBL] [Abstract][Full Text] [Related]
34. Clinical Features of Fecal Immunochemical Test-Negative Colorectal Lesions based on Colorectal Cancer Screening among Asymptomatic Participants in Their 50s.
Suto S; Matsuzaka M; Sawaya M; Sakuraba H; Mikami T; Matsuda T; Fujii T; Saito Y; Hotta K; Ikematsu H; Hanabata N; Saito H; Yoshida S; Fukuda S
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2325-2332. PubMed ID: 35901338
[TBL] [Abstract][Full Text] [Related]
35. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
[TBL] [Abstract][Full Text] [Related]
36. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).
Saito H; Kudo SE; Takahashi N; Yamamoto S; Kodama K; Nagata K; Mizota Y; Ishida F; Ohashi Y
Int J Colorectal Dis; 2020 May; 35(5):933-939. PubMed ID: 32034490
[TBL] [Abstract][Full Text] [Related]
38. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
39. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
